|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 31/529 | |
| A61K 31/519 | |||
| A61K 31/5355 | |||
| A61K 31/56 | |||
| A61K 39/395 | |||
| A61K 45/06 | |||
| A61P 37/06 |
| (11) | Number of the document | 3355891 |
| (13) | Kind of document | T |
| (96) | European patent application number | 16852514.5 |
| Date of filing the European patent application | 2016-09-28 | |
| (97) | Date of publication of the European application | 2018-08-08 |
| (45) | Date of publication and mention of the grant of the patent | 2021-01-13 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2016/054231 |
| Date | 2016-09-28 |
| (87) | Number | WO 2017/058950 |
| Date | 2017-04-06 |
| (30) | Number | Date | Country code |
| 201562233715 P | 2015-09-28 | US |
| (72) |
BETTS, Brian C., US
YU, Xuezhong, US
ANASETTI, Claudio, US
|
| (73) |
CTI Biopharma Corp.,
3101 Western Avenue 600, Seattle, Washington 98121,
US
|
| (54) | PACRITINIB FOR USE IN TREATING TRANSPLANT REJECTION |
| PACRITINIB FOR USE IN TREATING TRANSPLANT REJECTION |